Lv21
170 积分 2024-07-23 加入
The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant
1小时前
待确认
How I Treat Older Patients ative Acute Lymphoblastic Leukemia
6天前
已完结
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma
29天前
已完结
The current landscape of frontline large B cell lymphoma trials
1个月前
已完结
Management of post-autologous transplant relapse in patients with T-cell lymphomas
1个月前
已完结
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.Lancet Haematol
2个月前
已完结
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
2个月前
已完结
Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study. J Clin Oncol. 2024;42(suppl 16):7007. doi:10.1200/JCO.2024.42.16_suppl.70072. Wang M, Jurczak W, Trneny M, et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 SYMPATICO study
2个月前
已关闭
皖公网安备34019202002308
